Levin Capital Strategies L.P. Boosts Stock Position in Aura Biosciences, Inc. (NASDAQ:AURA)

Levin Capital Strategies L.P. lifted its position in Aura Biosciences, Inc. (NASDAQ:AURA) by 169.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,247,619 shares of the company’s stock after buying an additional 783,984 shares during the quarter. Levin Capital Strategies L.P. owned approximately 2.50% of Aura Biosciences worth $10,255,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Charles Schwab Investment Management Inc. raised its holdings in shares of Aura Biosciences by 2.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company’s stock valued at $1,233,000 after buying an additional 3,612 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in Aura Biosciences during the 4th quarter worth $87,000. State Street Corp grew its stake in Aura Biosciences by 3.7% during the 3rd quarter. State Street Corp now owns 754,803 shares of the company’s stock worth $6,725,000 after purchasing an additional 26,841 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Aura Biosciences by 107.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 53,502 shares of the company’s stock worth $477,000 after purchasing an additional 27,718 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Aura Biosciences by 4.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,008,827 shares of the company’s stock worth $8,990,000 after purchasing an additional 39,379 shares in the last quarter. Hedge funds and other institutional investors own 96.75% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. HC Wainwright reissued a “buy” rating and set a $22.00 target price on shares of Aura Biosciences in a research note on Thursday, November 14th. Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a research note on Friday, January 31st. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $23.00.

Aura Biosciences Stock Performance

NASDAQ:AURA opened at $7.49 on Friday. The stock has a 50-day simple moving average of $7.88 and a 200-day simple moving average of $8.70. The stock has a market cap of $374.13 million, a P/E ratio of -4.33 and a beta of 0.29. Aura Biosciences, Inc. has a 1 year low of $6.63 and a 1 year high of $12.38.

Insider Transactions at Aura Biosciences

In related news, insider Los Pinos Elisabet De sold 15,955 shares of the company’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total value of $122,374.85. Following the completion of the sale, the insider now directly owns 304,692 shares of the company’s stock, valued at $2,336,987.64. This represents a 4.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders sold 23,045 shares of company stock valued at $177,242. 5.40% of the stock is currently owned by corporate insiders.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.